探索"新优药械"从研发到使用的高效对接机制，优化临床急危重症抢救不可替代新药的入院流程，逐步 实现由30个工作日缩减至15个工作日。 为持续鼓励创新药品、医疗器械产品的实际应用，上海的政策支持不断升级。 日前，上海印发《上海市全面深化药品医疗器械监管改革促进医药产业高质量发展的若干措施》（下称 《若干措施》），提出六个方面共22项内容，通过监管制度的改革，来助推药械产业发展。这也是继 2024年7月上海出台《关于支持生物医药产业全链条创新发展的若干意见》（下称《若干意见》）后， 又一次大力度的政策指引。 加快创新产品应用 创新药械产品如何在审批、应用阶段提速是企业重点关切。为此，《若干措施》提出"加快创新产品应 用"，即"持续优化完善我市新上市药品挂网服务，积极申请成为新上市药品首发挂网省份""探索'新优 药械'从研发到使用的高效对接机制，优化临床急危重症抢救不可替代新药的入院流程，逐步实现由30 个工作日缩减至15个工作日""对符合规定的'新优药械'产品，及时研究纳入医保支付范围，鼓励商业健 康险产品覆盖更多'新优药械'"等。 第一财经了解到，与《若干意见》相协同的《上海市生物医药"新优药械"产品目录》今年 ...

Core Insights - The establishment of Shenzhen's first pharmaceutical and medical device industry overseas joint venture aims to connect local companies with global markets, enhancing export capabilities [1] - Shenzhen is a leader in high-end medical device exports, with significant metrics ranking it among the top in the country [1] - In 2024, Shenzhen's pharmaceutical and medical device industry is projected to have the highest export total among major cities, accounting for 12.9% of the national total [1] Group 1 - The joint venture consists of manufacturers, professional service institutions, and industry associations [1] - The initiative is part of Shenzhen's "Double Hundred Action" to accelerate the overseas expansion of its pharmaceutical and medical device sectors [1] - The joint venture aims to create an accelerator for local pharmaceutical and medical device companies to explore international markets [1] Group 2 - Shenzhen's performance in the high-end medical device export sector is highlighted as particularly strong [1] - The city's export total for the pharmaceutical and medical device industry is expected to lead among major cities in 2024 [1] - The national export share of Shenzhen's pharmaceutical and medical device industry is projected to be 12.9% [1]

Core Insights - Shenzhen has established its first pharmaceutical and medical device industry overseas joint venture to enhance global market access and accelerate the internationalization of local enterprises [1][2] Group 1: Industry Overview - Shenzhen's pharmaceutical and medical device exports are projected to lead major cities in China in 2024, accounting for 12.9% of the national total [1] - The total export value of medical devices from Shenzhen reached 29.8 billion yuan, with a year-on-year growth of 12.3%, representing 21.3% of the national export share [1] - Pharmaceutical exports from Shenzhen totaled 11.5 billion yuan, with a continuous increase in national share, reaching 6.4% in 2024 [1] Group 2: Joint Venture Structure - The joint venture is initiated by leading companies such as Kexing Pharmaceutical and Mindray Medical, along with other prominent firms like Health元 and Haipru [2] - It includes collaboration with professional service institutions in insurance, consulting, legal, and logistics sectors to create a comprehensive support ecosystem for overseas expansion [2] - The joint venture will establish specialized committees for pharmaceutical and medical device exports, facilitating access to international resources and market entry [2] Group 3: Future Initiatives - The joint venture plans to conduct a series of activities including brand promotion, training, and participation in international exhibitions to showcase Shenzhen's pharmaceutical and medical device innovations [2] - It aims to organize training on legal regulations, product registration, and market analysis, enhancing the capabilities of local enterprises for international operations [2] - The initiative will focus on collective participation in international exhibitions across regions such as Europe, South America, and Central Asia to enhance the global visibility of Shenzhen's pharmaceutical and medical device industry [2]